Triple-positive breast cancer refers to patients with positive estrogen receptor, positive progesterone receptor and positive HER-2 receptor. If triple-positive breast cancer is diagnosed early, the most effective treatment is surgery, including traditional modified radical surgery, or breast-conserving surgery if the patient is young. Postoperative treatment is determined by the patient’s pathological stage, lymph node metastasis and tumor biological behavior. For triple-positive breast cancer patients, they should undergo chemotherapy after surgery, most commonly cyclophosphamide, fluorouracil, epirubicin or paclitaxel. Such treatment can significantly improve the survival of patients. In case of HER-2(+) patients, targeted therapy can be given at the same time, and targeted therapy can significantly improve the cure rate of patients. One year of targeted therapy is also required after the chemotherapy cycle, along with long-term endocrine therapy with specific drugs such as triamcinolone acetonide or aromatase inhibitors.